Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

70.04B

Market cap70.04B

Price-Earnings ratio

16.15

Price-Earnings ratio16.15

Dividend yield

0.55%

Dividend yield0.55%

Average volume

876.09K

Average volume876.09K

High today

$669.16

High today$669.16

Low today

$660.80

Low today$660.80

Open price

$660.99

Open price$660.99

Volume

672.19K

Volume672.19K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

The current Regeneron(REGN) stock price is $665.00, with a market capitalization of 70.04B. The stock trades at a price-to-earnings (P/E) ratio of 16.15 and offers a dividend yield of 0.55%.

On 2026-07-09, Regeneron(REGN) stock moved within a range of $660.80 to $669.16. With shares now at $665.00, the stock is trading +0.6% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 672.19K, compared to an average daily volume of 876.09K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $821.11 and a low of $541.00.

REGN News

TipRanks 16h

Regeneron price target lowered to $854 from $855 at Piper Sandler

Piper Sandler analyst Biren Amin lowered the firm’s price target on Regeneron (REGN) to $854 from $855 and keeps an Overweight rating on the shares. The firm up...

MarketWatch 1d

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

...

Simply Wall St 3d

Regeneron Pharmaceuticals Could Be 22% Below Fair Value After Cemdisiran Review Win

Regeneron Pharmaceuticals (REGN) has drawn fresh attention after regulators in the US and Europe accepted cemdisiran for review in generalized myasthenia gravis...

Analyst ratings

71%

of 31 ratings

Buy

71%

Hold

29%

Sell

More REGN News

Simply Wall St 5d

Should Cemdisiran’s Priority Reviews and First-in-Class siRNA Status Require Action From Regeneron Investors?

In June 2026, Regeneron Pharmaceuticals announced that the FDA and EMA accepted regulatory applications for cemdisiran to treat anti-acetylcholine receptor anti...

Simply Wall St 6d

Regeneron Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions

Regeneron Pharmaceuticals stock has delivered a 20.2% return over the past year, and with a high value score plus an undervalued read on market multiples, the c...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.